EBO2 (EBOO) for Lyme Disease: What the Evidence Does and Doesn't Show

EBO2 (also called EBOO) is marketed to people with a Lyme disease diagnosis, especially those who have been told they have chronic Lyme disease after antibiotics did not resolve their symptoms. The pitch usually centers on inflammation, immune support, and clearing toxins from the blood rather than a specific claim about killing bacteria, though some clinic pages go further and suggest the therapy targets the infection directly. This guide sets out what Lyme disease treatment guidelines recommend, what a search of the published literature turns up for ozone and Lyme disease specifically, and what to ask before paying for a course of sessions.

Why Lyme patients look at EBO2

Most people with early Lyme disease recover fully after a course of antibiotics [1]. A minority continue to report fatigue, joint pain, or cognitive symptoms for months after treatment ends, a pattern CDC calls Post-Treatment Lyme Disease Syndrome (PTLDS) [3]. Some patients in this position, along with others who received a chronic Lyme diagnosis without a confirmed infection, look outside the antibiotic-based standard of care. EBO2 fits a pattern common in that market: clinics describe it as addressing the body’s overall inflammatory and toxic burden rather than targeting Borrelia burgdorferi, the bacterium that causes Lyme disease [6][7]. A similar framing shows up in marketing aimed at people with mold-related illness, another diagnosis where patients have often run out of options inside conventional care.

What Lyme disease is and how guidelines treat it

Lyme disease is a bacterial infection spread by the bite of an infected tick. Most cases can be treated with 10 days to 4 weeks of antibiotics, commonly doxycycline, amoxicillin, or cefuroxime axetil, and people treated early in the disease usually recover rapidly and completely [1]. CDC also notes that in certain circumstances a single dose of doxycycline given shortly after a recognized tick bite in an area where Lyme disease is common can lower the risk of developing the infection at all, an option to discuss with a clinician rather than a reason to delay standard care [1]. The 2020 clinical practice guideline from the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR), the professional societies whose members diagnose and treat this disease, sets out specific antibiotics and durations for early localized disease, neurologic Lyme disease, Lyme carditis, and Lyme arthritis, generally recommending 14 to 28 days of therapy depending on the manifestation [2]. Nowhere in that guideline is ozone therapy, EBO2, or EBOO mentioned. Blood filtration and ozone exposure play no role in the recommended treatment pathway at any stage of the disease.

The chronic Lyme disease controversy

Chronic Lyme disease is a contested label, and the controversy matters here because it is the label under which most EBO2-for-Lyme marketing operates. CDC discourages the term because it implies that prolonged symptoms are caused by an ongoing bacterial infection when the actual cause is not established, and prefers PTLDS for patients who had a confirmed Lyme infection and appropriate antibiotic treatment but still feel unwell [3]. Some practitioners apply chronic Lyme disease more broadly, including to patients without confirmed infection, and treat it with long courses of antibiotics or with alternative therapies outside the guideline. CDC’s own review of case reports describes patients given this diagnosis receiving extended antibiotics lasting months to years, IV infusions of hydrogen peroxide, immunoglobulin therapy, hyperbaric oxygen therapy, electromagnetic frequency treatments, garlic supplements, colloidal silver, and stem cell transplants, a list that illustrates how far this treatment market has drifted from anything in the guideline [4]. Five randomized, placebo-controlled trials have found that extended antibiotic treatment does not durably improve these prolonged symptoms compared with placebo: a 2001 publication reporting two separate placebo-controlled trials, one in seropositive and one in seronegative patients, both stopped early for futility [9]; a 2003 double-masked, placebo-controlled trial that found ceftriaxone improved fatigue scores but not cognitive function or a laboratory infection marker [10]; a 2008 placebo-controlled trial of repeated IV antibiotics for Lyme encephalopathy [11]; and a 2016 placebo-controlled trial of three longer-term regimens that found no significant difference in quality of life between any active treatment and placebo [12]. CDC states that long-term antibiotic use has been linked to serious complications including sepsis and colitis [3]. EBO2 is generally marketed to this same population: people already told their symptoms are Lyme-related, who have not improved on a first course of antibiotics, and who are now considering therapies CDC’s own guidance treats as unproven rather than merely undecided.

What the evidence shows

No controlled trial of EBO2, or of any other form of ozone therapy, has been conducted in people with Lyme disease. A PubMed search combining ozone with Borrelia, the genus of bacteria that causes Lyme disease, returns no results: no in-vitro study, no animal study, and no clinical trial. A broader search combining ozone with Lyme by name returns four results, and none of them test ozone against Lyme disease or Borrelia; they concern unrelated subjects such as the health costs of climate-related events. The closest thing to a relevant paper is a single-author narrative review arguing that ozone therapy could serve as an anti-infective approach against emerging pathogens; it mentions tick-borne infections once, as an example of the kind of disease its author believes ozone therapy might eventually address, and presents no Lyme-specific or Borrelia-specific data of any kind [5]. That review is also one physician’s argument rather than a systematic assessment of trial evidence, which limits how much weight it can carry even on the general question of ozone and infection.

This absence matters for a specific reason. Even if a laboratory study someday showed that ozone inactivates Borrelia in a test tube, that would not establish that a roughly one-hour extracorporeal blood treatment reaches and affects an infection that can persist in joints, connective tissue, and the nervous system, tissues EBO2 does not directly treat. The gap between an effect shown in a dish and a benefit shown in a patient is the same gap that has undermined long-term antibiotic regimens for persistent Lyme symptoms when those regimens were actually tested in trials, and no such trial exists yet for EBO2 to close that gap one way or the other.

Risks specific to this population

Patients considering EBO2 for Lyme disease face risks beyond those described in the general explanation of the procedure. Repeated IV access over a course of sessions carries a real, if generally low, risk of infection at the insertion site, a relevant concern for anyone whose immune system is already a source of worry to them. Cost is a separate factor: clinics bill EBO2 out of pocket, commonly in the hundreds to low thousands of dollars per session, and a multi-session package marketed as a Lyme protocol can run to several thousand dollars with no insurance contribution, since ozone therapy is not FDA-approved to treat any condition [8]. The least visible risk is opportunity cost. CDC’s own published case series describes five patients who received long courses of unproven treatments, including IV infusions, for a chronic Lyme diagnosis. One died of septic shock from a catheter-associated bloodstream infection after receiving IV ceftriaxone and cefotaxime; another developed an Acinetobacter bloodstream infection requiring intensive care and vasopressor support; a third developed a Pseudomonas aeruginosa spinal infection that destroyed part of a vertebra; a fourth developed Clostridium difficile colitis that persisted for more than two years; and a fifth developed a Staphylococcus aureus bloodstream infection with a paraspinal abscess requiring surgical drainage [4]. EBO2 was not among the specific therapies named in that report, but it shares the same basic exposure as the therapies that were: an invasive, unproven treatment given through IV access to a patient who may be delaying further evaluation of symptoms that could have another explanation.

Questions to ask a clinic that recommends it

A patient offered EBO2 for Lyme disease can reasonably ask what published study supports its use for this condition, and whether the answer describes a controlled trial or a mechanism argument extrapolated from unrelated laboratory work on other organisms. It is fair to ask whether the clinic has confirmed an active infection through standard testing, and whether EBO2 is being proposed instead of, or alongside, guideline-based antibiotics. Asking how many sessions are recommended and at what total cost before starting avoids the pressure of an open-ended package once money is already committed. Anyone with a recent tick bite, an erythema migrans rash, or another early sign of Lyme disease should ask directly why antibiotics, the treatment with an actual trial-based evidence record, are not the immediate plan. It is also worth asking a clinic directly whether they have treated documented cases of Lyme carditis or neurologic Lyme disease, manifestations the guideline treats as more serious and time-sensitive than early localized infection, since a clinic confident enough to manage those presentations without falling back on standard antibiotics would be an outlier worth scrutinizing carefully. This site’s clinic directory is a starting point for comparing what different clinics say and charge, not an endorsement of any of them.

Bottom line

Lyme disease has an antibiotic-based standard of care with a substantial evidence base, set out in a joint IDSA, AAN, and ACR guideline that does not mention ozone therapy in any form [2]. No controlled trial, and no PubMed-indexed laboratory study, has tested EBO2 or any other ozone-based treatment against Borrelia burgdorferi specifically. Patients who finish antibiotics and still feel unwell have a real, named condition in PTLDS [3], but CDC’s own data describe documented harm from further unproven treatment rather than a demonstrated benefit from it [4]. Anyone considering EBO2 for Lyme disease symptoms should discuss it with a clinician who follows the guideline before paying for sessions marketed as a Lyme protocol, and should treat a clinic’s willingness to bypass that guideline entirely as a signal to get a second opinion rather than as a sign of more advanced or personalized care.